Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVERLAST: Everolimus and Lenvatinib in Advanced Bone Sarcoma
NCT07619950Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Jul 2026
- Primary completion
- Nov 2028
01
Overview
A Phase 2 trial of lenvatinib in bone sarcoma, sponsored by Yonsei University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
bone sarcoma
Beyond the preview
Go deeper on NCT07619950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07619950.